Previous close | 0.0001 |
Open | 0.0001 |
Bid | 0.0001 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0001 - 0.0001 |
52-week range | 0.0001 - 0.0027 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares of th
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have